Quantcast

Latest TroVax Stories

2010-11-10 08:00:00

WORCESTER, Mass., Nov. 10, 2010 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTC Bulletin Board: GNBT) announced today that its wholly-owned immunotherapeutics subsidiary, Antigen Express, Inc.

2010-10-27 02:21:47

Even though the cancer-treatment agent cetuximab is not considered effective treatment for KRAS (a gene)-mutated metastatic colorectal tumors, new research indicates that patients with colorectal cancer not responding to chemotherapy and a certain variation of this gene who were treated with cetuximab had longer overall and progression-free survival than patients with other KRAS-mutations.

2010-10-12 13:53:00

CINCINNATI, Oct. 12 /PRNewswire-USNewswire/ -- A clinical trial testing a genetically reprogrammed herpes simplex virus as treatment for deadly forms of childhood cancer has received a U.S.

2010-09-21 05:02:00

TUEBINGEN, Germany, September 21, 2010 /PRNewswire/ -- - New Investment Allows immatics to Perform Pivotal Study With its Lead Vaccine IMA901 in Patients With Renal Cell Carcinoma (RCC) - Study to Start in 2010 - IMA901 Phase II Trial has Shown the Potential to Confer an Overall Survival Benefit - Financing Supported by Both New and Existing Investors immatics biotechnologies GmbH, a biopharmaceutical company developing advanced therapeutic vaccines that are active...

2010-09-08 13:44:51

Lung cancer researchers have identified a genetic signature that can help doctors determine which patients with early-stage non-small cell lung cancer are at high risk for developing disease recurrence and therefore may benefit from chemotherapy after surgery ("adjuvant chemotherapy").

2010-08-19 15:17:00

BRUSSELS, August 19, 2010 /PRNewswire/ -- Using the innovative technique of radioembolisation to treat patients with inoperable colorectal cancer liver metastases who have failed all standard-of-care chemotherapy options can more than double the time until their disease progresses, according to the final results of a Phase III randomised controlled trial published in the prestigious Journal of Clinical Oncology.(1) The prospective, randomised trial compared a protracted infusion of...

2010-06-24 07:00:00

SAN CARLOS, Calif., June 24 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that the first patients have been dosed in a new Phase 1 dose-escalation clinical study to evaluate NKTR-102, the company's lead oncology compound, in combination with 5-fluorouracil (5-FU)/leucovorin in refractory solid tumor cancers.


Word of the Day
metagrabolized
  • totally perplexed and mixed up.
The word 'metagrabolized' is also spelled 'metagrobolized'.
Related